Metabolic and vascular determinants of impaired cognitive performance and abnormalities on brain magnetic resonance imaging in patients with type 2 diabetes

Diabetologia

Volumn 50, Issue 11, 2007, Pages 2388-2397

  Manschot, S M ^a   Biessels, G J ^a   De Valk, H ^b   Algra, A ^b   Rutten, G E H M ^b   Van Der Grond, J ^c   Kappelle, L J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Brain atrophy; Brain MRI; Cerebral complications; Cognitive performance; Diabetic encephalopathy; Metabolic risk factors; Neuropsychological investigation; Type 2 diabetes mellitus; Vascular risk factors; White matter lesions

Indexed keywords

INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BRAIN ATROPHY; BRAIN INFARCTION; CARDIOVASCULAR RISK; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; DIET THERAPY; DISEASE ASSOCIATION; FEMALE; GLUCOSE METABOLISM; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; NEUROIMAGING; NEUROPATHY; NEUROPSYCHOLOGICAL TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETINOPATHY; SCORING SYSTEM; WHITE MATTER;

AGED; BRAIN; BRAIN MAPPING; COGNITION DISORDERS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEUROPATHIES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; REFERENCE VALUES;

EID: 34848835838     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-007-0792-z     Document Type: Article

References (49)

1. Gispen WH, Biessels GJ (2000) Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 23:542-549
2. Allen KV, Frier BM, Strachan MW (2004) The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol 490:169-175
3. Stewart R, Liolitsa D (1999) Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med 16:93-112
4. Schmidt R, Launer LJ, Nilsson LG et al (2004) Magnetic resonance imaging of the brain in diabetes: the Cardiovascular Determinants of Dementia (CASCADE) Study. Diabetes 53:687-692
5. den Heijer T, Vermeer SE, van Dijk EJ et al (2003) Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 46: 1604-1610
6. Manschot SM, Brands AM, van der Grond GJ et al (2006) Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes 55:1106-1113
7. Elias PK, Elias MF, D'Agostino RB et al (1997) NIDDM and blood pressure as risk factors for poor cognitive performance. The Framingham Study. Diabetes Care 20:1388-1395
8. Asimakopoulou KG, Hampson SE, Morrish NJ (2002) Neuropsychological functioning in older people with type 2 diabetes: the effect of controlling for confounding factors. Diabet Med 19:311-316
9. Kanaya AM, Barrett-Connor E, Gildengorin G, Yaffe K (2004) Change in cognitive function by glucose tolerance status in older adults: a 4-year prospective study of the Rancho Bernardo study cohort. Arch Intern Med 164:1327-1333
10. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R (2005) Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 65:545-551
11. Sheetz MJ, King GL (2002) Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 288:2579-2588
12. Cameron NE, Eaton SE, Cotter MA, Tesfaye S (2001) Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 44:1973-1988
13. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R (1998) Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure and hyperglycemia. Arch Intern Med 158(9):998-1004
14. No authors listed (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 317: 703-713
15. Tesfaye S, Chaturvedi N, Eaton SE et al (2005) Vascular risk factors and diabetic neuropathy. N Engl J Med 352:341-350
16. de Leeuw FE, de Groot JC, Bots ML et al (2000) Carotid atherosclerosis and cerebral white matter lesions in a population based magnetic resonance imaging study. J Neurol 247:291-296
17. Breteler MM, Claus JJ, Grobbee DE, Hofman A (1994) Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. BMJ 308:1604-1608
18. van Exel E, Gussekloo J, Houx P et al (2002) Atherosclerosis and cognitive impairment are linked in the elderly. The Leiden 85-plus Study. Atherosclerosis 165:353-359
19. Breteler MM, van-Swieten JC, Bots ML et al (1994) Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study. Neurology 44:1246-1252
20. American Diabetes Association (1998) Report of the Expert Committee on diagnosis and classification of diabetes mellitus. Diabetes Care 21:S5-S19
21. Beck A, Ward C, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561-571
22. Scheltens P, Barkhof F, Leys D et al (1993) A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 114:7-12
23. Gomori JM, Steiner I, Melamed E, Cooper G (1984) The assessment of changes in brain volume using combined linear measurements. A CT-scan study. Neuroradiology 26:21-24
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
25. Klein R, Klein BE, Magli YL et al (1986) An alternative method of grading diabetic retinopathy. Ophthalmology 93:1183-1187
26. Bril V, Perkins BA (2002) Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. Diabetes Care 25:2048-2052
27. Rose GA, Blackburn H, Gillurn RF, Prineas RJ (1982) Cardiovascular survey methods. Report of the World Health Organization. WHO, Geneva
28. Bisschops RH, Klijn CJ, Kappelle LJ, van Huffelen AC, van der Grond J (2003) Association between impaired carbon dioxide reactivity and ischemic lesions in arterial border zone territories in patients with unilateral internal carotid artery occlusion. Arch Neurol 60:229-233
29. Vermeer SE, den Heijer T, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM (2003) Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 34:392-396
30. van Harten B, de Leeuw FE, Weinstein HC, Scheltens P, Biessels GJ (2006) Brain imaging in patients with diabetes: a systematic review. Diabetes Care 29:2539-2548
31. Perlmuter LC, Hakami MK, Hodgson-Harrington C et al (1984) Decreased cognitive function in aging non-insulin-dependent diabetic patients. Am J Med 77:1043-1048
32. Zaslavsky LM, Gross JL, Chaves ML, Machado R (1995) Memory dysfunction and autonomic neuropathy in non-insulin-dependent (type 2) diabetic patients. Diabetes Res Clin Pract 30:101-110
33. Wessels AM, Simsek S, Remijnse PL et al (2006) Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy. Diabetologia 49:2474-2480
34. Musen G, Lyoo IK, Sparks CR et al (2006) Effects of type 1 diabetes on gray matter density as measured by voxel-based morphometry. Diabetes 55:326-333
35. Brands AM, Biessels GJ, De Haan EH, Kappelle LJ, Kessels RP (2005) The Effects of type 1 diabetes on cognitive performance: a meta-analysis. Diabetes Care 28:726-735
36. Craft S, Watson GS (2004) Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3:169-178
37. Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Horwitz RI (2002) Insulin resistance and risk for stroke. Neurology 59:809-815
38. de Leeuw FE, de Groot JC, Oudkerk M et al (1999) A follow-up study of blood pressure and cerebral white matter lesions. Ann Neurol 46:827-833
39. Elias MF, Wolf PA, D'Agostino RB, Cobb J, White LR (1993) Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol 138:353-364
40. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K (2005) Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64:277-281
41. Qiu C, Winblad B, Fratiglioni L (2005) The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 4:487-499
42. Hassing LB, Hofer SM, Nilsson SE et al (2004) Comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: evidence from a longitudinal study. Age Ageing 33:355-361
43. Fontbonne A, Berr C, Ducimetiere P, Alperovitch A (2001) Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: Results of the Epidemiology of Vascular Aging Study. Diabetes Care 24:366-370
44. Shobab LA, Hsiung GY, Feldman HH (2005) Cholesterol in Alzheimer's disease. Lancet Neurol 4:841-852
45. Pico F, Dufouil C, Levy C et al (2002) Longitudinal study of carotid atherosclerosis and white matter hyperintensities: the EVA-MRI cohort. Cerebrovasc Dis 14:109-115
46. Costa LA, Canani LH, Lisboa HR, Tres GS, Gross JL (2004) Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in type 2 diabetes. Diabet Med 21:252-255
47. Spijkerman AM, Henry RM, Dekker JM et al (2004) Prevalence of macrovascular disease amongst type 2 diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the Hoorn Screening Study. J Intern Med 256:429-436
48. Goudswaard AN, Stolk RP, Zuithoff P, Rutten GE (2004) Patient characteristics do not predict poor glycaemic control in type 2 diabetes patients treated in primary care. Eur J Epidemiol 19:541-545
49. Hochstenbach J, Mulder T, van Limbeek J, Donders R, Schoonderwaldt H (1998) Cognitive decline following stroke: a comprehensive study of cognitive decline following stroke. J Clin Exp Neuropsychol 20:503-517